Pediatrics Doctors in Fpo, AP Accepting Medicare

6 Pediatrics doctors found. Showing 1 - 6

Dr. Lynn Ann Bailey, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Usnh Yokosuka Japan, Psc 475 Box 1, Fpo, AP 96350 Phone: 011-814-68968728

Katherine Maureen Carlin, MD Pediatrics Medicare: Medicare Enrolled Practice Location: Us Naval Hospital Okinawa, Camp Foster, Fpo, AP 96362 Phone: 315-646-7488

Dr. Thomas Arthur Pluim Ii, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: Psc 490, Box 7668, Fpo, AP 96530 Phone: 671-486-5084

Meghan Leigh Jarman, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Usnh Okinawa, Fpo, AP 96362 Phone: 315-646-7488

Dr. Frances Lauren Rosario, M.D., MPH Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 315-243-5505

Dr. Heather Soloria, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: U.s. Naval Hospital Guam, Psc 455, Fpo, AP 96540 Phone: 671-344-9543

News Archive

SGK1 enzyme protects brain cells in animal models of Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have found how a widely known but little-studied enzyme protects brain cells in models of Parkinson's disease.

Emergence of diabetes could be monitored using our Google searches

The emergence of Type 2 Diabetes could be more effectively monitored using our Google searches - helping public health officials keep track of the disease and halt its spread - according to research by the University of Warwick.

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere's QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

IDRI launches LEISH-F3 + GLA-SE Phase 1 trial for kala-azar

The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place in Washington State, with a companion Phase 1 trial planned in India, an epicenter of the disease.

Read more Medical News

› Verified 5 days ago